Oncology Corporate Profile
Kolltan, a privately held clinical-stage company, is advancing a new generation of therapeutics in oncology and other diseases by creating novel biologic agents that can modulate the function of receptor tyrosine kinases (RTKs). Kolltan has a unique understanding of RTKs, their ligands, and cellular signaling and has assembled a team with significant expertise and unique insight into these drug targets.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|KTN-3379||anti-erbb3 monoclonal antibody||Various cancer types||I|